MGI PHARMA significantly expanded its late-stage pipeline of product candidates with the completion of four business development transactions in 2004. In addition, the New Drug Application (NDA) for Dacogen™ (decitabine) for Injection in myelodysplastic syndromes (MDS) was submitted to the U.S. Food and Drug Administration (FDA).